European marketing authorization application for MOB-015 submitted

STOCKHOLM, March 28, 2022 /PRNewswire/ -- Moberg Pharma AB (publ) have submitted its marketing authorization application for MOB-015 (nail fungus treatment). The company has submitted the application in Europe through the decentralized procedure, and market approval is expected in 2023.

Moberg Pharma have submitted a full application, which offers the possibility of data exclusivity in Europe for up to ten years following market approval. The Swedish Medical Products Agency is the reference member state and will lead the review of the application. The company's goal is to receive its first market approval and launch MOB-015 in 2023.

"Submitting the Marketing Authorization Application in Europe is a key milestone in our journey to launch a new and improved nail fungus drug. MOB-015 is uniquely positioned through its high antifungal efficacy, since there is significant need for a treatment that truly cures the nail infection," says Anna Ljung, CEO of Moberg Pharma AB.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: [email protected]

About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 a.m. CET on March 28^th, 2022.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/moberg-pharma/r/european-marketing-authorization-application-for-mob-015-submitted,c3529030

The following files are available for download:

SOURCE Moberg Pharma